Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NB004 in Advanced Solid Tumors
NCT05036291Phase 1Terminated
- Sponsor
- Ningbo NewBay Technology Development Co., Ltd.
- Start
- Oct 2021
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of NB004 in solid tumor (advanced stage) (2 arms), sponsored by Ningbo NewBay Technology Development Co., Ltd. Primary endpoints: Incidence of dose-limiting toxicities at 28 days, Incidence of adverse events at 24 months and 6 more. Started Oct 2021; status: terminated.
02
Drugs
NB004
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05036291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05036291.